"Thromboxanes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Physiologically active compounds found in many organs of the body. They are formed in vivo from the prostaglandin endoperoxides and cause platelet aggregation, contraction of arteries, and other biological effects. Thromboxanes are important mediators of the actions of polyunsaturated fatty acids transformed by cyclooxygenase.
| Descriptor ID |
D013931
|
| MeSH Number(s) |
D10.251.355.255.100.825 D10.251.355.310.166.971
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thromboxanes".
Below are MeSH descriptors whose meaning is more specific than "Thromboxanes".
This graph shows the total number of publications written about "Thromboxanes" by people in this website by year, and whether "Thromboxanes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thromboxanes" by people in Profiles.
-
Barton BA, Kronsberg SS, Hariri E, Vasan RS, Rade GA, Xanthakis V, Kickler TS, Rade JJ. Adjustment for Renal Function Improves the Prognostic Performance of Urinary Thromboxane Metabolites. Clin Chem. 2024 04 03; 70(4):660-668.
-
Hariri E, Kakouros N, Bunsick DA, Russell SD, Mudd JO, Laws K, Lake MW, Rade JJ. Nonplatelet thromboxane generation is associated with impaired cardiovascular performance and mortality in heart failure. Am J Physiol Heart Circ Physiol. 2022 07 01; 323(1):H248-H255.
-
Rade JJ, Barton BA, Vasan RS, Kronsberg SS, Xanthakis V, Keaney JF, Hamburg NM, Kakouros N, Kickler TA. Association of Thromboxane Generation?With Survival in Aspirin?Users?and Nonusers. J Am Coll Cardiol. 2022 07 19; 80(3):233-250.
-
Gleim S, Stitham J, Tang WH, Li H, Douville K, Chelikani P, Rade JJ, Martin KA, Hwa J. Human thromboxane A2 receptor genetic variants: in silico, in vitro and "in platelet" analysis. PLoS One. 2013; 8(6):e67314.
-
Tang WH, Stitham J, Gleim S, Di Febbo C, Porreca E, Fava C, Tacconelli S, Capone M, Evangelista V, Levantesi G, Wen L, Martin K, Minuz P, Rade J, Patrignani P, Hwa J. Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J Clin Invest. 2011 Nov; 121(11):4462-76.
-
Freedman JE. Heritability, platelet function, and aspirin: a link established but cause unknown. Circulation. 2007 May 15; 115(19):2468-70.
-
Hrboticky N, Tang L, Zimmer B, Lux I, Weber PC. Lovastatin increases arachidonic acid levels and stimulates thromboxane synthesis in human liver and monocytic cell lines. J Clin Invest. 1994 Jan; 93(1):195-203.
-
Lorenz R, Weber PC. Thromboxane as diagnostic tool and therapeutic target in cardiovascular disease. Eicosanoids. 1992; 5 Suppl:S53-5.
-
Uedelhoven WM, Meese CO, Weber PC. Analysis of the major urinary thromboxane metabolites, 2,3-dinorthromboxane B2 and 11-dehydrothromboxane B2, by gas chromatography-mass spectrometry and gas chromatography-tandem mass spectrometry. J Chromatogr. 1989 Dec 29; 497:1-16.
-
Weber PC. Clinical studies on the effects of n-3 fatty acids on cells and eicosanoids in the cardiovascular system. J Intern Med Suppl. 1989; 731:61-8.